PORT WASHINGTON, NY – October 3, 2018: Pall Corporation, a global leader in filtration, separation and purification, has progressed a strategic partnership with the University College London (UCL) Biochemical Engineering department with the creation of the UCL-Pall Biotech Centre of Excellence (CoE) for research and training.

The UCL-Pall Biotech CoE will be operational from September 2018 through 2024 with a management committee supported by UCL’s Strategic Alliance Director, Naveraj Gill. The investment in the UCL Biochemical Engineering’s industrial research collaboration program with Pall Biotech is valued at £2.7M ($3.5M) and is staffed by nine Engineering Doctorates (EngDs) and a fully funded Post-Doctoral Research Associate. The organizations will engage in multi-level interactions to enable knowledge transfer and address critical industry challenges.

“This alliance is another example of Pall Biotech’s commitment to continuously improve bioprocesses through strategic partnerships,” said Mario Philips, Vice President and General Manager, Pall Biotech. “There is value that comes from working closely with partners – it allows our team to take a holistic approach to research that addresses core interests and industry challenges.”


“For many years we have collaborated with the Pall Biotech team to overcome industry challenges at the supply level. The new CoE will work to enhance drug production and empower the future workforce,” Naveraj Gill said. “UCL colleagues Daniel Bracewell, Professor of Bioprocess Analysis and Mike Hoare, Professor of Biochemical Engineering will bring this vision to life internally. Rick Morris, Senior Vice President, Pall Biotech R&D, Richard Gutman, Distinguished Fellow and John Welsh, Senior Manager Pall Biotech Process R&D will align with us externally.”


Ranked as a top-ten university worldwide, UCL is known for encouraging students, staff, and partners to find new ways to convert discovery into commercially viable solutions that have  an impact. The Biochemical Engineering department takes a unique multidisciplinary approach focused on translational research with strategic partners, such as major pharmaceutical manufacturers or suppliers like Pall Biotech, to gain real-life insight into the most pressing industry challenges. The new CoE is just one example of how UCL remains driven to deliver on business objectives and priorities globally.


About Pall Corporation

Pall Corporation is a filtration, separation and purification leader, providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. For more information visit www.pall.com


Or follow us on social media: YouTubeLinkedIn - Twitter - Facebook


About UCL Biochemical Engineering

Ranked as one of the top ten world universities and recognized as the leading London-based multi- faculty institute, our research addresses challenges in the three most important sectors of the advanced bioprocessing industries. The Industrial Biotechnology group focuses on biocatalysis and the sustainable synthesis of chemicals and pharmaceuticals from renewable resources. The Macromolecular Medicines group addresses the manufacture of advanced biopharmaceutical therapies including antibodies, genes and recombinant vaccines. Finally, the Cell Therapy Bioprocessing group is concerned with the translation of stem cell science into novel cell and tissue-based therapies.


Our outstanding reputation derives from a shared passion to understand how life science discoveries can be converted into commercially viable products on a truly global scale. Proud winners of Queens Anniversary Trust Award (2013) for pioneering studies for the bioprocessing industry. For more information visit: www.ucl.ac.uk/biochemeng or contact Naveraj.gill@ucl.ac.uk


Pall Corporate Media Contact

Pall Corporation

Mariann Kourafas

Director of Communications


Pall Biotech Media Contact

White Matter Communications

Beth Willers



More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
April 2020
Pall joins a consortium led by Oxford University in fast-tracking clinical trials for a COVID-19 vaccine beginning April 2020.